TherapeuticsMD (NASDAQ: TXMD) reported Q1 EPS of ($5.69), $1.69 worse than the analyst estimate of ($4.00). Revenue for the quarter came in at $19.3 million versus the consensus estimate of $17.95 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.